Lexeo Therapeutics is a company developing gene therapy for people with FA cardiomyopathy. They recently announced the completion of the first cohort in their Phase I/II trial, testing their gene therapy called LX2006. Â
In the first cohort, LX2006 was well tolerated with no unexpected events observed. Based on this, they have begun dosing the second cohort of participants. This is a 52-week trial taking place in America. They expect results from this trial in the first half of 2024.Â
Read more in the Lexeo Therapeutics press release.
